Moving Forward with Metronomic Chemotherapy: Meeting Report of
the 2nd International Workshop on Metronomic and
Anti-Angiogenic Chemotherapy in Paediatric Oncology

J 2011

Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology

PASQUIER, Eddy, Mark W. KIERAN, Jaroslav ŠTĚRBA, Yuval SHAKED, Sylvain BARUCHEL et. al.

Základní údaje

Originální název

Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology

Autoři

PASQUIER, Eddy (36 Austrálie, garant), Mark W. KIERAN (840 Spojené státy), Jaroslav ŠTĚRBA (203 Česká republika, domácí), Yuval SHAKED (376 Izrael), Sylvain BARUCHEL (124 Kanada), Odile OBERLIN (250 Francie), Maria Sanna KIVIVUORI (246 Finsko), Andreas PEYRL (40 Rakousko), Mamouna DIAWARRA (466 Mali), Michaela CASANOVA (380 Itálie), Stergios ZACHAROULIS (826 Velká Británie a Severní Irsko), Gilles VASSAL (250 Francie), Franck BERTHOLD (276 Německo), Arnauld VERSCHUUR (250 Francie) a Nicolas ANDRE (250 Francie)

Vydání

TRANSLATIONAL ONCOLOGY, 2011, 1936-5233

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.393

Kód RIV

RIV/00216224:14110/11:00055931

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1593/tlo.11124

UT WoS

000294253200001

Klíčová slova anglicky

ENDOTHELIAL PROGENITOR CELLS; SOLID TUMORS; ORAL ETOPOSIDE; BRAIN-TUMORS; ANTIANGIOGENIC THERAPY; DOSE CYCLOPHOSPHAMIDE; BREAST-CANCER; CHILDREN; RECURRENT; FUTURE

Příznaky

Mezinárodní význam

Změněno: 5. 3. 2012 11:58, Mgr. Michal Petr

Anotace

V originále

Metronomic chemotherapy, which is defined by the frequent, repetitive administration of chemotherapeutic drugs at relatively low doses, and without prolonged drug-free break, is an emerging strategy to fight cancer. Initially thought to act by targeting tumor angiogenesis, additional mechanisms have been recently unveiled, and metronomic chemotherapy is now considered to represent a form of multitargeted therapy. Despite representing a genuine alternative for advanced and/or high-risk cancer therapy, the development of metronomic approaches in pediatric oncology still in the early stage. The few numbers of large-scale state-of-the-art clinical trials, issues regarding terminology and the limited understanding of the complex and intertwined mechanisms of action of metronomic treatments have limited progress in this important field of research. On March 18 and 19, 2010, the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology was held in Marseille, France, and brought together clinicians, basic scientists, physician-scientists, trainees, and students from all around the world. The main aim of this international meeting was to provide a unique forum to 1) reflect on the major advances that have been made in this field of research since its creation, 2) communicate results from the most recent clinical trials and preclinical studies, 3) discuss the current and future challenges of the field, and 4) set forth a solid framework for future collaborative biologic and clinical studies. The present report documents the main preclinical and clinical data that were presented in the keynote and best abstract sessions and delivers the key messages from the meeting.

Citovat

PASQUIER, Eddy, Mark W. KIERAN, Jaroslav ŠTĚRBA, Yuval SHAKED, Sylvain BARUCHEL, Odile OBERLIN, Maria Sanna KIVIVUORI, Andreas PEYRL, Mamouna DIAWARRA, Michaela CASANOVA, Stergios ZACHAROULIS, Gilles VASSAL, Franck BERTHOLD, Arnauld VERSCHUUR a Nicolas ANDRE. Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. TRANSLATIONAL ONCOLOGY. 2011, roč. 4, č. 4, s. 189-197. ISSN 1936-5233. Dostupné z: https://dx.doi.org/10.1593/tlo.11124.

@article{974264,
   author = {Pasquier, Eddy and Kieran, Mark W. and Štěrba, Jaroslav and Shaked, Yuval and Baruchel, Sylvain and Oberlin, Odile and Kivivuori, Maria Sanna and Peyrl, Andreas and Diawarra, Mamouna and Casanova, Michaela and Zacharoulis, Stergios and Vassal, Gilles and Berthold, Franck and Verschuur, Arnauld and Andre, Nicolas},
   article_number = {4},
   doi = {http://dx.doi.org/10.1593/tlo.11124},
   keywords = {ENDOTHELIAL PROGENITOR CELLS; SOLID TUMORS; ORAL ETOPOSIDE; BRAIN-TUMORS; ANTIANGIOGENIC THERAPY; DOSE CYCLOPHOSPHAMIDE; BREAST-CANCER; CHILDREN; RECURRENT; FUTURE},
   language = {eng},
   issn = {1936-5233},
   journal = {TRANSLATIONAL ONCOLOGY},
   title = {Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology},
   volume = {4},
   year = {2011}
}

TY  - JOUR
ID  - 974264
AU  - Pasquier, Eddy - Kieran, Mark W. - Štěrba, Jaroslav - Shaked, Yuval - Baruchel, Sylvain - Oberlin, Odile - Kivivuori, Maria Sanna - Peyrl, Andreas - Diawarra, Mamouna - Casanova, Michaela - Zacharoulis, Stergios - Vassal, Gilles - Berthold, Franck - Verschuur, Arnauld - Andre, Nicolas
PY  - 2011
TI  - Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology
JF  - TRANSLATIONAL ONCOLOGY
VL  - 4
IS  - 4
SP  - 189-197
EP  - 189-197
SN  - 19365233
KW  - ENDOTHELIAL PROGENITOR CELLS
KW  - SOLID TUMORS
KW  - ORAL ETOPOSIDE
KW  - BRAIN-TUMORS
KW  - ANTIANGIOGENIC THERAPY
KW  - DOSE CYCLOPHOSPHAMIDE
KW  - BREAST-CANCER
KW  - CHILDREN
KW  - RECURRENT
KW  - FUTURE
N2  - Metronomic chemotherapy, which is defined by the frequent, repetitive administration of chemotherapeutic drugs at relatively low doses, and without prolonged drug-free break, is an emerging strategy to fight cancer. Initially thought to act by targeting tumor angiogenesis, additional mechanisms have been recently unveiled, and metronomic chemotherapy is now considered to represent a form of multitargeted therapy. Despite representing a genuine alternative for advanced and/or high-risk cancer therapy, the development of metronomic approaches in pediatric oncology still in the early stage. The few numbers of large-scale state-of-the-art clinical trials, issues regarding terminology and the limited understanding of the complex and intertwined mechanisms of action of metronomic treatments have limited progress in this important field of research. On March 18 and 19, 2010, the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology was held in Marseille, France, and brought together clinicians, basic scientists, physician-scientists, trainees, and students from all around the world. The main aim of this international meeting was to provide a unique forum to 1) reflect on the major advances that have been made in this field of research since its creation, 2) communicate results from the most recent clinical trials and preclinical studies, 3) discuss the current and future challenges of the field, and 4) set forth a solid framework for future collaborative biologic and clinical studies. The present report documents the main preclinical and clinical data that were presented in the keynote and best abstract sessions and delivers the key messages from the meeting.
ER  -

PASQUIER, Eddy, Mark W. KIERAN, Jaroslav ŠTĚRBA, Yuval SHAKED, Sylvain BARUCHEL, Odile OBERLIN, Maria Sanna KIVIVUORI, Andreas PEYRL, Mamouna DIAWARRA, Michaela CASANOVA, Stergios ZACHAROULIS, Gilles VASSAL, Franck BERTHOLD, Arnauld VERSCHUUR a Nicolas ANDRE. Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. \textit{TRANSLATIONAL ONCOLOGY}. 2011, roč.~4, č.~4, s.~189-197. ISSN~1936-5233. Dostupné z: https://dx.doi.org/10.1593/tlo.11124.

Podrobný výpis o publikaci